Contributors
Aashruti Agrawal(National Institute of Pharmaceutical Education and Research - Ahmedabad), Ravi Shankar Prasad Singh(Pfizer (United States)), Ayesha Khan, Keerti Mishra(Central Drug Research Institute), Dharmendra Kumar Khatri(NIMS University), Monica Gulati(Lovely Professional University), Jayabalan Nirmal(Birla Institute of Technology and Science - Hyderabad Campus), Nitin Jain(Parul University), Ravi Raj Pal(Babasaheb Bhimrao Ambedkar University), Sarwar Beg(Jamia Hamdard), Charu Misra, Dhara Jain, Ketan Patel(University of Reading), Harshita Dalvi(National Institute of Pharmaceutical Education and Research - Ahmedabad), Purva Pingle(National Institute of Pharmaceutical Education and Research - Ahmedabad), Amruta Gorajiya(Amneal (India)), M. Arockia Babu(GLA University), Manali Patki(St. John's University), Venkatesh Teja Banala(Central Drug Research Institute), Nidhi Mishra, Neelesh Kumar Mehra(National Institute of Pharmaceutical Education and Research - Ahmedabad), Praveen Lakhera, Padakanti Sandeep Chary(Florida Agricultural and Mechanical University), Raquibun Nisha, Rakesh Kumar Paul, Valamla Bhavana(National Institute of Pharmaceutical Education and Research - Ahmedabad), Kiran Jyoti, Isha Joshi, Jatinder Kaur Mukker(Merck Serono S.p.A. (Italy)), Faria Ali(Jamia Hamdard), Indrani Maji, Mimansa Goyal(St. John's University), Preeti Kush(Shobhit University), Dhrubojyoti Mukherjee, Priyanka Maurya, Jitender Madan(National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad), Srushti Mahajan, Vineela Parvathaneni(St. John's University), Akash Chaurasiya(Birla Institute of Technology and Science - Hyderabad Campus), Mohd. Aqil(Hamdard University), Yige Fu(St. John's University), Aditi Bhat(National Institute of Pharmaceutical Education and Research - Ahmedabad), Manpreet Kaur(Hebrew University of Jerusalem), Parveen Kumar, Vivek Gupta(St. John's University), Farhan Jalees Ahmad(Jamia Hamdard), Harsha Jain(National Institute of Pharmaceutical Education and Research - Ahmedabad), Manish K. Chourasia(Central Drug Research Institute), Alka(Babasaheb Bhimrao Ambedkar University), Vikas Chaudhary(Central Scientific Instruments Organisation)
Cited by 0
Related Papers
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
|American Journal of Hematology|2017|437